Mycophenolate Mofetil Hydrochloride

Decreases mycophenolic acid systemic exposure and may reduce Mycophenolate Mofetil efficacy. Administer at least 2 hours after Mycophenolate Mofetil.

Bile acid sequestrant that interferes with enterohepatic recirculation, decreasing mycophenolic acid systemic exposure and potentially reducing Mycophenolate Mofetil efficacy.

Interferes with enterohepatic recirculation, decreasing mycophenolic acid systemic exposure and potentially reducing Mycophenolate Mofetil efficacy. Monitor for alterations.

Inhibits glucuronidation, increasing mycophenolic acid systemic exposure and potentially increasing risk of Mycophenolate Mofetil adverse reactions. Monitor for alterations.

Proton pump inhibitor that decreases mycophenolic acid systemic exposure and may reduce Mycophenolate Mofetil efficacy. Monitor for alterations in efficacy.

Decreases mycophenolic acid systemic exposure and may reduce Mycophenolate Mofetil efficacy. Administer at least 2 hours after Mycophenolate Mofetil.

Mycophenolate Mofetil may reduce effectiveness of oral contraceptives. Use of additional barrier contraceptive methods is recommended.

Proton pump inhibitor that decreases mycophenolic acid systemic exposure and may reduce Mycophenolate Mofetil efficacy. Monitor for alterations in efficacy.

Interferes with enterohepatic recirculation and induces glucuronidation, decreasing mycophenolic acid systemic exposure and potentially reducing Mycophenolate Mofetil efficacy.

Interferes with enterohepatic recirculation, decreasing mycophenolic acid systemic exposure and potentially reducing Mycophenolate Mofetil efficacy. Monitor for alterations.

Induces glucuronidation, decreasing mycophenolic acid systemic exposure and potentially reducing Mycophenolate Mofetil efficacy. Monitor for alterations.

Examples Acyclovir, ganciclovir, probenecid, valacyclovir, valganciclovir Combination Oral Contraceptives Clinical Impact Concomitant use with Mycophenolate Mofetil decreased the systemic exposure to levonorgestrel, but did not affect the systemic exposure to ethinylestradiol [see Clinical Pharmacology (12.3) ] , which may result in reduced combination oral contraceptive effectiveness.

Examples Acyclovir, ganciclovir, probenecid, valacyclovir, valganciclovir Combination Oral Contraceptives Clinical Impact Concomitant use with Mycophenolate Mofetil decreased the systemic exposure to levonorgestrel, but did not affect the systemic exposure to ethinylestradiol [see Clinical Pharmacology (12.3) ] , which may result in reduced combination oral contraceptive effectiveness.

Examples Cyclosporine A, trimethoprim/sulfamethoxazole, bile acid sequestrants (cholestyramine), rifampin as well as aminoglycoside, cephalosporin, fluoroquinolone and penicillin classes of antimicrobials Drugs Modulating Glucuronidation Clinical Impact Concomitant use with drugs inducing glucuronidation decreases MPA systemic exposure, potentially reducing Mycophenolate Mofetil efficacy, while use with drugs inhibiting glucuronidation increases MPA systemic exposure [see Clinical Pharmacology (12.3) ] , which may increase the risk of Mycophenolate Mofetil related adverse reactions.

Examples Cyclosporine A, trimethoprim/sulfamethoxazole, bile acid sequestrants (cholestyramine), rifampin as well as aminoglycoside, cephalosporin, fluoroquinolone and penicillin classes of antimicrobials Drugs Modulating Glucuronidation Clinical Impact Concomitant use with drugs inducing glucuronidation decreases MPA systemic exposure, potentially reducing Mycophenolate Mofetil efficacy, while use with drugs inhibiting glucuronidation increases MPA systemic exposure [see Clinical Pharmacology (12.3) ] , which may increase the risk of Mycophenolate Mofetil related adverse reactions.

Examples Acyclovir, ganciclovir, probenecid, valacyclovir, valganciclovir Combination Oral Contraceptives Clinical Impact Concomitant use with Mycophenolate Mofetil decreased the systemic exposure to levonorgestrel, but did not affect the systemic exposure to ethinylestradiol [see Clinical Pharmacology (12.3) ] , which may result in reduced combination oral contraceptive effectiveness.

Examples Acyclovir, ganciclovir, probenecid, valacyclovir, valganciclovir Combination Oral Contraceptives Clinical Impact Concomitant use with Mycophenolate Mofetil decreased the systemic exposure to levonorgestrel, but did not affect the systemic exposure to ethinylestradiol [see Clinical Pharmacology (12.3) ] , which may result in reduced combination oral contraceptive effectiveness.